Celiac Disease in Children: Case Discussion & Key Points
Model Case Presentation
Patient Demographics
Name: Miss Priya, Age: 3 years, Gender: Female, Informant: Mother (Reliable)
Chief Complaints
- Chronic, recurrent, foul-smelling loose stools – 8 months
- Abdominal distension – 6 months
- Poor weight gain and reduced activity – 6 months
History Summary
Child was apparently well until 7 months of age when wheat-containing foods (roti, bread) were introduced. Gradually developed loose, pale, bulky, greasy stools (3–5 per day) with offensive odour. Stools float in water. Associated with progressive abdominal distension, irritability, and loss of appetite. No blood in stools. No vomiting. Weight was adequate up to 6 months, then faltered. No family history of similar illness. No recent travel or contact with a diarrheal illness. Mother noted the child's buttocks appear wasted ("wasted buttocks").
Born at term via NVD, cried immediately. Birth weight 2.9 kg. Exclusive breastfeeding for 6 months. Immunisation up to date. Non-consanguineous marriage.
Examination Summary
| Parameter | Finding | Significance |
|---|---|---|
| Weight | 9 kg (expected ~14 kg) | Severe Failure to Thrive (< -3 SD) |
| Height | 84 cm (expected ~94 cm) | Stunting |
| MUAC | 12 cm | Moderate acute malnutrition |
| Abdomen | Distended, doughy feel | Classical celiac abdomen |
| Muscle bulk | Wasted buttocks, thin thighs | Malabsorption with muscle wasting |
| Pallor | Present (mild) | Iron deficiency / folate deficiency anaemia |
| Oedema | Absent | — |
| Clubbing | Absent | — |
Abdomen: Distended. Doughy consistency on palpation. No organomegaly. Bowel sounds normal. No ascites. Prominent veins not seen.
Skin/nails: Pallor of conjunctivae. Angular stomatitis. No dermatitis herpetiformis (uncommon in young children).
Neurological: Irritable. No ataxia.
✅ Complete Diagnosis
Celiac Disease (Gluten-Sensitive Enteropathy) — Classical Presentation in a 3-year-old, with Severe Failure to Thrive, Stunting, Chronic Malabsorption, and Iron-Deficiency Anaemia secondary to Gluten Enteropathy.
📝 History — Exam Q&A
Celiac disease (CD) is a chronic, immune-mediated enteropathy triggered by the ingestion of gluten (a protein found in wheat, barley, and rye) in genetically predisposed individuals. It is characterised by small intestinal villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis, leading to malabsorption. It resolves on a strict lifelong gluten-free diet (GFD).
Global prevalence: approximately 0.7–1% of the general population (affects ~1 in 100 people). In India, celiac disease is increasingly recognised, particularly in North India (Punjab, Haryana, Delhi), where wheat forms the staple diet. Prevalence in North India is reported around 0.3–1%. It is far more common than traditionally believed. It is twice as common in females.
| Gluten-Containing (AVOID) | Safe (Gluten-Free) |
|---|---|
| Wheat (maida, atta, semolina/sooji, daliya) | Rice |
| Barley (jau) | Maize/Corn |
| Rye | Millet (jowar, bajra, ragi) |
| Triticale (wheat-rye hybrid) | Sorghum |
| Oats* (often contaminated) | Buckwheat (kuttu) |
| Amaranth (rajgira), Quinoa, Tapioca |
💡 Note on Oats
Pure, uncontaminated oats are tolerated by most celiac patients (they contain avenin not gliadin), but commercial oats in India are usually contaminated with wheat during processing — so they are best avoided unless certified gluten-free.
Classic GI presentation: 9 months to 2 years of age — after gluten-containing complementary foods are introduced. Onset is typically 4–8 weeks after gluten introduction. However, CD can present at any age. Older children and adolescents more often present with atypical/extra-intestinal manifestations. Triggers for late-onset CD may include infections, surgery, pregnancy, or stress.
The classical "celiac triad" in young children:
- Chronic diarrhoea — loose, pale, bulky, greasy, foul-smelling stools that float (steatorrhoea)
- Abdominal distension — pot-belly appearance with doughy feel on palpation
- Failure to thrive — weight faltering after gluten introduction, with muscle wasting (particularly buttocks and thighs)
Child is typically irritable, miserable, and anorexic. Contrast with the well-nourished, cheerful appearance before gluten introduction.
| System | Manifestation |
|---|---|
| Haematological | Iron-deficiency anaemia (most common), folate/B12 deficiency, rarely thrombocytosis |
| Growth | Short stature, delayed puberty |
| Bones | Osteopenia, osteoporosis, rickets (rare), fractures |
| Neurological | Ataxia, peripheral neuropathy, epilepsy (with occipital calcifications – celiac-epilepsy-cerebral calcifications triad) |
| Dermatological | Dermatitis herpetiformis (pathognomonic skin manifestation) |
| Dental | Enamel hypoplasia of permanent teeth |
| Hepatic | Elevated transaminases (celiac hepatitis), autoimmune hepatitis |
| Endocrine | Type 1 DM (associated), thyroid disease, Addison's disease |
| Oral | Recurrent aphthous ulcers, angular stomatitis |
| Reproductive | Infertility, recurrent abortions (in adolescent/adult females) |
| Psychiatric | Irritability, depression, anxiety |
Dermatitis herpetiformis (DH) is a pathognomonic skin manifestation of celiac disease. It presents as intensely itchy, symmetrical, grouped blisters (vesicles) and erythematous papules over the elbows, knees, buttocks, and scalp. It is caused by IgA deposits in the dermal papillae. Most patients with DH have subclinical small bowel involvement. Diagnosis is confirmed by skin biopsy showing granular IgA deposits at the dermoepidermal junction on immunofluorescence. Dapsone rapidly relieves itching; gluten-free diet treats the underlying disease.
💡 Pearl
DH is more common in adolescents and adults. It is very rare in children under 5 years. Do not expect to see DH in a young child with classical GI presentation.
- First-degree relatives of a diagnosed celiac patient (~10–15% risk)
- Type 1 Diabetes Mellitus (~5–10% have CD)
- Down Syndrome (~5–12% have CD)
- Turner Syndrome (~3–5% have CD)
- Williams Syndrome
- Selective IgA deficiency (~10% have CD)
- Autoimmune thyroid disease
- Autoimmune hepatitis
- Children with unexplained iron deficiency anaemia, short stature, or chronic elevated transaminases
Celiac disease has a strong genetic basis:
- HLA-DQ2 (encoded by HLA-DQA1*05 and HLA-DQB1*02): Present in ~90–95% of celiac patients
- HLA-DQ8 (encoded by HLA-DQA1*03 and HLA-DQB1*0302): Present in most of the remaining ~5–10%
- Virtually all celiac patients carry HLA-DQ2 or HLA-DQ8
- However, ~30–40% of the general population also carries these alleles, so it is necessary but NOT sufficient for diagnosis
- HLA typing is used to rule OUT celiac disease (negative predictive value ~99%) — if neither DQ2 nor DQ8, celiac disease is very unlikely
- Concordance in identical twins: ~75–80% — suggesting non-HLA genes and environmental factors also contribute
Celiac disease requires three components: gluten + HLA susceptibility + immune dysregulation.
- Gluten ingestion: Gliadin fraction of gluten is partially digested in the intestinal lumen.
- Mucosal permeability: Gliadin peptides cross the intestinal epithelium into the lamina propria.
- Deamidation by tTG: Tissue Transglutaminase (tTG) deamidates gliadin peptides → creates negatively charged epitopes that bind strongly to HLA-DQ2/DQ8 molecules on antigen presenting cells (APCs).
- T cell activation: CD4+ T cells recognize gliadin-DQ2/DQ8 complexes → release pro-inflammatory cytokines (IFN-γ, TNF-α) → villous atrophy and crypt hyperplasia.
- Humoral immunity: B cells produce anti-tTG IgA, anti-endomysial IgA antibodies — used diagnostically.
- Result: Villous blunting → reduced absorptive surface area → malabsorption of fat, carbohydrates, proteins, iron, calcium, folate, B12.
- No blood in stools — helps rule out inflammatory bowel disease
- No tenesmus — against colitis
- No fever, no contact with enteric illness — rules out infectious diarrhoea
- No recurrent respiratory infections — against cystic fibrosis
- No oil droplets in stools — distinguishes from Abetalipoproteinemia
- No family history of early death or infertility — rules out CF in older adolescents
- Gluten temporal relationship — symptoms began after wheat introduction (crucial clue)
| Type | Description |
|---|---|
| Classical | GI symptoms (diarrhoea, FTT, abdominal distension) + positive serology + villous atrophy |
| Non-classical (Atypical) | Extra-intestinal symptoms (anaemia, short stature, dental defects) + positive serology + villous atrophy |
| Subclinical (Silent) | No symptoms. Positive serology + villous atrophy. Found on screening (e.g., family members, T1DM) |
| Potential | Positive serology but normal intestinal histology (Marsh 0 or 1). At risk of developing full CD |
| Refractory | Persistent symptoms/villous atrophy despite strict GFD for >12 months (rare, associated with complications) |
| Seronegative | Villous atrophy + compatible histology, but negative serology. Rare (~5%); often IgA deficient |
🩺 Examination — Exam Q&A
The classical celiac "triad" on inspection:
- Pot belly (abdominal distension) — due to gas, poor intestinal motility, and atonic abdominal muscles from malnutrition
- Wasted buttocks and proximal limbs — severe muscle wasting despite the protruding abdomen
- Pale, miserable-looking child — irritable, anorexic, apathetic
The contrast between a distended abdomen and thin, wasted buttocks ("spider-man belly with matchstick legs") is very characteristic.
- Weight: Plot on WHO/IAP growth chart. Calculate weight-for-age Z-score (WAZ). Below -2 SD = underweight; below -3 SD = severe.
- Height/Length: Height-for-age Z-score (HAZ). Below -2 SD = stunting (indicates chronic malnutrition).
- Weight-for-Height: WHZ or BMI-for-age. Below -2 SD = wasting (acute malnutrition).
- MUAC: Mid-upper arm circumference. < 12.5 cm (6 months–5 years) = acute malnutrition. < 11.5 cm = severe.
- Head circumference: Important in younger infants; reflects brain growth.
In celiac disease: chronic malnutrition → stunting predominates. Long-standing cases show wasting + stunting.
- Inspection: Pot belly / abdominal distension. Visible peristalsis (not typical). No visible veins.
- Palpation: Doughy consistency — characteristic, due to gas-filled hypotonic bowel and loss of abdominal muscle tone. No organomegaly (hepatomegaly rare). No palpable mass.
- Percussion: Resonant (gas-filled loops). No shifting dullness (no ascites in typical celiac).
- Auscultation: Bowel sounds normal or mildly increased.
💡 Doughy Abdomen
The "doughy" feel of the celiac abdomen is due to a combination of flabby abdominal muscles (from malnutrition) and gas-distended atonic bowel loops — a useful clinical sign to remember.
| Deficiency | Clinical Sign |
|---|---|
| Iron | Pallor, koilonychia, glossitis, angular stomatitis |
| Folate/B12 | Pallor, glossitis, megaloblastic anaemia signs |
| Vitamin D / Calcium | Bow legs, knock knees, craniotabes, rachitic rosary (if co-existing rickets) |
| Vitamin A | Night blindness (rare), Bitot spots |
| Vitamin K | Easy bruising, petechiae, prolonged bleeding |
| Zinc | Acrodermatitis (perianal/perioral rash), poor wound healing, growth failure |
| Protein | Oedema (if severe hypoproteinaemia), hair changes |
The characteristic stool of celiac disease reflects steatorrhoea (fat malabsorption):
- Pale/clay-coloured — due to fat content (bile pigments diluted by fat)
- Bulky and large — unabsorbed fat and carbohydrates add bulk
- Greasy/oily — fat globules visible
- Offensive, foul smell — bacterial fermentation of unabsorbed carbohydrates and proteins
- Floats on water — due to high fat and gas content (positive "floating stool" sign)
- Frequency: 3–5 stools per day (less frequent than infective diarrhoea)
- No blood, no mucus — distinguishes from IBD and infective colitis
| Age Group | Predominant Presentation |
|---|---|
| Infants (6 months–2 yrs) | Classical: diarrhoea, abdominal distension, FTT, irritability, muscle wasting. Most dramatic presentation. |
| Older children (2–10 yrs) | Mix of GI and extra-intestinal. Short stature, anaemia, recurrent abdominal pain, constipation may be prominent. |
| Adolescents | Often atypical/subclinical. Short stature, delayed puberty, menstrual irregularity, fatigue, depression, dental enamel defects, DH. GI symptoms may be minimal. |
Key concept: The "iceberg model" — classical GI celiac is just the tip. The larger base consists of atypical, silent, and potential celiac disease that goes undiagnosed.
Celiac crisis is a rare, life-threatening acute decompensation in a patient with celiac disease, characterised by:
- Profuse, watery diarrhoea leading to severe dehydration
- Electrolyte imbalances — hyponatraemia, hypokalaemia, hypomagnesaemia, hypocalcaemia
- Metabolic acidosis
- Hypoproteinaemia with oedema
- Coagulopathy (Vitamin K deficiency)
- Profound muscle weakness
Management: IV fluids, electrolyte correction, IV corticosteroids (to rapidly reduce inflammation), followed by gluten-free diet. Requires ICU care.
Triggers include intercurrent infection, surgical stress, or non-adherence to GFD with a large gluten load.
🔬 Investigations — Exam Q&A
The initial investigation is serology. The recommended first-line test is:
- Anti-tissue Transglutaminase IgA (anti-tTG IgA) — highest sensitivity (~95–98%) among available tests
- Always order Total serum IgA simultaneously to detect IgA deficiency (which can cause false-negative anti-tTG IgA)
Both tests should be sent together as the initial screen.
| Test | Sensitivity | Specificity | Notes |
|---|---|---|---|
| Anti-tTG IgA | ~95–98% | ~90–95% | First-line test. Best sensitivity. |
| Anti-Endomysial IgA (EMA-IgA) | ~90–95% | ~99–100% | Near-perfect specificity. Used as confirmatory second-line test. Operator-dependent (immunofluorescence). |
| Deamidated Gliadin Peptide IgG (DGP-IgG) | ~80–90% | ~90–95% | Useful when IgA deficient. Better than older AGA tests. |
| Anti-tTG IgG | Variable | Lower | Only use when total IgA is low. |
| Antigliadin IgA/IgG (AGA) | Low | Low | Obsolete — no longer recommended for routine screening (except children <2 yrs where AGA may be slightly more sensitive). |
🚨 IgA Deficiency — Critical Point
If total serum IgA is low for age (or <0.2 g/L above 3 years), anti-tTG IgA will be falsely negative. Use DGP IgG or anti-tTG IgG instead. Selective IgA deficiency itself is 10× more common in celiac patients than in the general population.
Intestinal biopsy (duodenal biopsy) with histopathology remains the gold standard for diagnosis in most patients. However, in children who meet specific criteria, diagnosis can now be made without biopsy (see no-biopsy strategy below).
Biopsy technique (ESPGHAN 2020 recommendation):
- At least 4 biopsies from the distal duodenum (D2 onwards)
- At least 1 biopsy from the duodenal bulb (D1) — patchy disease may be present only here
- Biopsies should be placed on cellulose acetate filter paper (Millipore) to ensure correct orientation
- Patient must be on a gluten-containing diet at the time of biopsy
| Marsh Grade | IEL* /100 enterocytes | Crypt Hyperplasia | Villi | Significance |
|---|---|---|---|---|
| 0 | <25 | No | Normal | Normal mucosa — CD unlikely |
| 1 | ≥25 (↑ IEL) | No | Normal | Infiltrative — seen in potential CD, DH, on GFD |
| 2 | ≥25 | Yes | Normal | Hyperplastic — rare, sometimes DH |
| 3a | ≥25 | Yes | Mild atrophy | Active CD |
| 3b | ≥25 | Yes | Marked atrophy (partial VA) | Active CD |
| 3c | ≥25 | Yes | Total villous atrophy (flat mucosa) | Severe/classical CD |
*IEL = Intraepithelial lymphocytes. Normal V:C (villous:crypt) ratio is 3:1. In celiac disease it is reversed.
💡 Exam Tip
Marsh 3 (especially 3b and 3c) = diagnostic of celiac disease in appropriate clinical context. Marsh 1-2 = non-specific (needs clinical and serological correlation). The minimum IEL threshold is 25 per 100 enterocytes (some use 30/100 — remember both figures may be mentioned in different textbooks).
Biopsy can be avoided in children if ALL of the following criteria are met:
- Anti-tTG IgA ≥ 10 times the upper limit of normal (10× ULN)
- Anti-EMA IgA positive (tested in a second blood sample)
- IgA sufficient (total IgA normal for age)
Note: ESPGHAN 2020 removed the mandatory HLA testing that was required in the earlier 2012 guidelines. The 2023 ACG guidelines also accept a no-biopsy approach in children meeting the above criteria (tTG-IgA ≥10× ULN alone has ~99% PPV in children).
🚨 Crucial Caveat
The patient must be on a gluten-containing diet at the time of testing. Starting a GFD before testing will cause falsely negative serology and make diagnosis unreliable. Never start GFD before establishing the diagnosis.
HLA-DQ2/DQ8 typing is not a routine first-line test. Its role is to rule OUT celiac disease:
- If HLA-DQ2 and HLA-DQ8 are BOTH negative → celiac disease is extremely unlikely (NPV ~99%). Patient does not need further evaluation.
- A positive result does NOT confirm CD (30–40% of general population carry these alleles)
Specific indications for HLA typing:
- Patients who started a GFD before formal diagnosis — to decide if gluten challenge is needed
- Inconclusive serology + histology (Marsh 1-2 with low positive tTG)
- Seronegative patients with villous atrophy — to support/exclude CD
- Asymptomatic high-risk individuals (Down syndrome, T1DM, family members) — to determine if ongoing serological surveillance is needed
- Stool for fat (Sudan III stain / faecal fat estimation): Positive fat globules (steatorrhoea). Quantitative 72-hr faecal fat > 7 g/day indicates fat malabsorption.
- D-xylose test: Reduced D-xylose absorption indicates small intestinal mucosal disease (now rarely done in practice).
- CBC: Microcytic hypochromic anaemia (iron deficiency) or macrocytic anaemia (folate/B12). Thrombocytosis may be seen.
- Serum iron, ferritin, folate, B12: Assess nutritional deficiencies.
- Serum albumin and total protein: Low in protein malabsorption / prolonged malnutrition.
- LFT: Elevated transaminases (celiac hepatitis — normalises on GFD).
- Serum calcium, phosphate, alkaline phosphatase, Vitamin D: May be low (malabsorption).
- PT/INR: Prolonged if severe Vitamin K deficiency.
- Thyroid function tests: Screen for associated autoimmune thyroid disease.
A gluten challenge involves reintroducing gluten in a patient who had previously been on a GFD (before formal diagnosis was established), to allow serological and/or histological confirmation of celiac disease.
Indications:
- Child started GFD before serological or biopsy confirmation
- Doubt about the original diagnosis
Protocol: Give at least 3–5 g of gluten per day (equivalent to 2 slices of bread) for a minimum of 4–8 weeks, then recheck serology. If still doubtful, repeat biopsy. Some centres do a 6-month trial.
Preferred timing: Not before age 5 years, not during puberty (unreliable antibody responses during rapid growth).
🚨 Not needed if:
HLA-DQ2 and HLA-DQ8 are both negative — celiac disease can be excluded without gluten challenge.
💊 Management — Exam Q&A
The only proven, effective treatment for celiac disease is a strict, lifelong Gluten-Free Diet (GFD). This means complete and permanent avoidance of wheat, barley, and rye. Rice, maize, millets (bajra, jowar, ragi), sorghum, buckwheat, and quinoa are safe alternatives.
Response to GFD is both therapeutic AND diagnostic — clinical improvement on GFD supports the diagnosis.
- Iron: Oral iron supplementation for iron-deficiency anaemia (3–6 mg/kg/day elemental iron). Expected response in 4–6 weeks.
- Folate: Oral folic acid supplementation if deficient.
- Vitamin B12: If deficient (especially in total villous atrophy affecting terminal ileum).
- Vitamin D and Calcium: Supplementation routinely recommended as malabsorption commonly leads to deficiency; important for bone health.
- Zinc: If deficient.
- Vitamin K: If coagulopathy present; parenteral Vitamin K for acute management.
- High-calorie, high-protein diet: Nutritional rehabilitation essential. Catch-up growth expected within 6–12 months of GFD.
Response monitoring uses clinical, serological, and occasionally histological parameters:
- Clinical: Improvement in stool frequency and consistency, reduction in abdominal distension, return of appetite, improvement in mood/irritability within 2–4 weeks of GFD.
- Growth: Weight gain typically begins within 1–3 months. Significant catch-up growth within 6–12 months. Linear growth (height) may take 1–2 years.
- Serology (anti-tTG IgA): Checked every 6 months until normalisation, then every 12–24 months thereafter (per 2024 guidelines). A falling tTG indicates dietary adherence and mucosal healing. Normalization expected by 12–24 months.
- CBC, iron studies, vitamins: Reassessed 3–6 monthly initially.
- Repeat biopsy: Not routinely required for monitoring in children. Considered if symptoms persist despite GFD (to diagnose non-responsive CD or refractory CD).
- Bone density (DXA scan): If evidence of metabolic bone disease or osteoporosis risk.
Most common cause: Inadvertent gluten ingestion (hidden gluten)
- Hidden gluten in sauces, soups, processed foods, medications, communion wafers
- Cross-contamination during cooking (shared utensils, toasters, fryers)
- Voluntary dietary transgressions (non-adherence) — very common in adolescents
Other causes to consider:
- Wrong diagnosis (not actually celiac disease)
- Concurrent conditions: Microscopic colitis, small intestinal bacterial overgrowth (SIBO), lactose intolerance (secondary), IBS, Crohn's disease
- Refractory celiac disease (Type I or II — very rare in children)
- Enteropathy-associated T-cell lymphoma (EATL) — a serious complication in refractory CD
- Ulcerative jejunitis
- Short stature — due to chronic malnutrition and growth hormone resistance
- Delayed puberty
- Iron-deficiency anaemia — resistant to oral iron therapy (resolves on GFD)
- Osteoporosis / Osteopenia — leading to fractures
- Infertility and recurrent abortions (in females)
- Neurological complications — ataxia, peripheral neuropathy, epilepsy
- Autoimmune diseases — increased risk of Type 1 DM, autoimmune thyroid, autoimmune hepatitis
- Malignancy — Enteropathy-Associated T-cell Lymphoma (EATL), small bowel adenocarcinoma, oropharyngeal cancer (rare; mainly in adults with long-standing untreated CD)
- Refractory celiac disease — poor prognosis, especially Type II (clonal T cells)
- Celiac crisis (see Examination tab)
- GFD is lifelong — emphasise even when completely asymptomatic; silent damage continues with gluten exposure
- Label reading — identify gluten in ingredient lists ("wheat starch," "modified starch," "atta," "maida," "semolina/sooji," "barley malt")
- Cross-contamination prevention — separate utensils, cooking surfaces, toasters; avoid frying in shared oil
- School meals and eating out — educate school staff; choose safe options cautiously
- Screen first-degree relatives — parents and siblings should be tested with tTG IgA
- Recurrence risk: ~10–15% in first-degree relatives (autosomal dominant with incomplete penetrance)
- Refer to a registered dietitian for detailed gluten-free diet planning
- Connect with celiac support groups
- Regular follow-up — serological monitoring and growth assessment
Yes. Despite the absence of symptoms, subclinical (silent) celiac disease should be treated with GFD because:
- Ongoing intestinal damage leads to silent malabsorption (iron, calcium, folate) even without symptoms
- Long-term risk of osteoporosis, anaemia, and potentially malignancy persists
- Increased risk of autoimmune complications
- GFD is safe and well-tolerated
However, the decision should be made after informed discussion with the family, acknowledging the lifelong dietary change required.
- IV fluid resuscitation — correct dehydration and electrolyte imbalances (Na, K, Mg, Ca)
- IV corticosteroids — methylprednisolone 1–2 mg/kg/day (rapidly reduces mucosal inflammation)
- Parenteral nutrition (TPN) if oral feeding not possible
- IV Vitamin K for coagulopathy
- Albumin infusion if severe hypoalbuminaemia
- Strict gluten-free diet as soon as oral intake resumes
- ICU monitoring
🔭 Recent Advances — Exam Q&A
Several drug therapies are under investigation as adjuncts to or replacements for GFD:
- Larazotide acetate — Tight junction regulator that reduces intestinal permeability. Reduces symptoms due to inadvertent gluten exposure. Phase III trials completed.
- Prolyl endopeptidases (glutenases) — e.g., ALV003, STAN1: Enzymes that degrade gluten in the gut before it can trigger an immune response. Phase II trials showed reduction in villous atrophy with inadvertent gluten exposure.
- Nexvax2 (gluten peptide vaccine): Failed in Phase 2 trial (2019). Efforts at immunotherapy continue.
- Anti-IL-15 therapy (CALY-002): Targets the cytokine driving intraepithelial lymphocyte activation. Under investigation for refractory CD.
- ZED1227 (TG2 inhibitor): Blocks tissue transglutaminase — the enzyme responsible for deamidating gliadin and triggering the immune response. Phase II trials showed significant mucosal protection.
- Indoximod (IDO pathway modulator): Under early investigation.
Currently, none of these drugs are approved for routine clinical use. GFD remains the only proven treatment.
The ESPGHAN 2020 guidelines (updated from 2012) made the following key changes:
- Biopsy-free diagnosis extended to asymptomatic children — the 2012 guidelines only allowed no-biopsy in symptomatic children. The 2020 update allows it in asymptomatic children too, if tTG-IgA ≥10× ULN and EMA IgA positive.
- HLA typing no longer mandatory for no-biopsy pathway — previously required in the 2012 guidelines as a third condition; now optional.
- Duodenal bulb biopsy emphasized — at least 1 biopsy from D1 (bulb) mandated for biopsy-based diagnosis, as patchy disease may be missed otherwise.
- Potential celiac disease defined more precisely — tTG/EMA positive but Marsh 0-1; manage with close follow-up (can treat with GFD if symptomatic).
Point-of-care (POC) tTG IgA tests (rapid tests) allow bedside or clinic-based testing using a finger-prick blood sample and give results in 10–15 minutes.
- Advantages: Rapid, simple, no laboratory required — useful in resource-limited settings and mass screening
- Performance: Good sensitivity (~95%) and specificity (~94%) compared to laboratory ELISA
- Limitation: Qualitative or semi-quantitative only — cannot reliably determine 10× ULN threshold needed for no-biopsy strategy. A positive POCT result should be confirmed with laboratory quantitative tTG IgA before proceeding with no-biopsy diagnosis.
- Useful as a screening tool in high-risk populations and mass screening programs
Early studies (ESPGHAN 1996) suggested small gluten exposure during breastfeeding reduced CD risk. However, two landmark RCTs — PREVENT CD and CELIPREV — showed:
- Neither the timing of gluten introduction (4 months vs. 6 months) nor breastfeeding status during introduction significantly affects the risk of developing celiac disease in genetically at-risk children
- Gluten introduction should follow standard complementary feeding guidelines (from 6 months per WHO/IAP recommendations)
Current recommendation: No specific timing manipulation for CD prevention. Gluten should not be delayed beyond 12 months as this also does not reduce risk and may increase it. Currently, no proven prevention strategy exists for celiac disease.
Emerging research shows that gut microbiome dysbiosis (altered composition of intestinal bacteria) is associated with celiac disease:
- Children with CD have reduced diversity of intestinal microbiota
- Decreased Lactobacillus and Bifidobacterium species; increased Bacteroides and E. coli
- Dysbiosis may influence intestinal permeability and immune regulation
- GFD partially but not completely restores microbiome composition
Probiotics and microbiome modulation are being studied as potential adjunct therapies, but no recommendation currently exists for routine probiotic use in celiac disease management.
⚡ Key Points — Quick Revision
One-Liners for Exam
- Definition: Chronic immune-mediated enteropathy triggered by gluten in genetically susceptible individuals
- Gluten in: Wheat, Barley, Rye (remember: WBR)
- Safe grains: Rice, Maize, Millets (bajra, jowar, ragi), Buckwheat, Quinoa
- Classic triad: Chronic diarrhoea + Abdominal distension + Failure to thrive
- Stool character: Pale, bulky, greasy, foul-smelling, floats (steatorrhoea)
- Pathognomonic skin lesion: Dermatitis herpetiformis (itchy blisters on elbows, knees, buttocks; IgA deposits on biopsy)
- First-line serology: Anti-tTG IgA + Total IgA
- Most specific test: Anti-EMA IgA (~99–100% specificity)
- Gold standard: Duodenal biopsy (Marsh classification 3b/3c = flat mucosa)
- No-biopsy diagnosis (children): tTG-IgA ≥10× ULN AND EMA IgA positive (ESPGHAN 2020 / ACG 2023)
- HLA DQ2/DQ8: Present in ~95% of celiac patients. Negative HLA rules out CD (NPV ~99%).
- IgA deficiency: Causes false-negative tTG IgA — use DGP IgG or tTG IgG instead
- Treatment: Lifelong strict GFD — the ONLY proven treatment
- Monitor: tTG IgA every 6 months till normalisation, then 12–24 monthly
- Celiac crisis: IV fluids + IV steroids + IV Vitamin K + TPN → life-threatening emergency
- High-risk groups: T1DM, Down syndrome, Turner syndrome, IgA deficiency, first-degree relatives
- Never start GFD before diagnosis — causes false-negative serology and biopsy
- Complications of untreated CD: Short stature, osteoporosis, anaemia, T-cell lymphoma (EATL), infertility
- Malignancy risk: EATL (Enteropathy-Associated T-cell Lymphoma) in adults with refractory/untreated CD
- Recurrence risk in siblings: ~10–15%
🧠 Differentials to Know
- Cystic fibrosis — steatorrhoea, FTT, but also recurrent chest infections; sweat chloride test distinguishes
- Giardiasis — chronic diarrhoea, FTT; stool microscopy shows trophozoites/cysts; responds to metronidazole
- Cow's Milk Protein Allergy (CMPA) — younger infants; dairy triggers symptoms; rash, eosinophilia possible
- Tropical sprue — adults, endemic areas; responds to antibiotics + folate
- Inflammatory Bowel Disease — blood/mucus in stools, fever, elevated CRP/ESR; colonoscopy differentiates
- Abetalipoproteinaemia — oil droplets in stool, acanthocytes in blood film, very low cholesterol, ataxia